Nirmal Bang has come out with its report on Indoco Remedies. The research firm is positive on the company with a long term perspective.
Nirmal Bang has come out with its report on Indoco Remedies . The research firm is positive on the company with a long term perspective.
“Indoco Remedies is one of the leading pharmaceutical players engaged in manufacturing of APIs and Formulations. Indoco’s business spread worldwide from regulated markets like US, Europe to semiregulated markets. The company has strong position in domestic therapeutics segments like Ophthalmology, Anti- Infectives etc. Recently it has achieved noteworthy milestones in its growth journey by tying up with big global Pharma companies like Watson, Aspen etc for contract manufacturing and other services.”
“Tie up with Global giants for CRAMS: During FY10 the company has signed two significant deals; one with Watson for US markets and second with Aspen for emerging markets. These are landmark deals in the history of the company. Since initial tie-up, the scope and size of the deal has only increased which shows the strong capabilities of the company. In these deals, Indoco is involved from development of the product (for some products) until manufacturing. These deals have brought the Indoco in the category of trusted offshore players like Cadila, Dr Reddy. Aspen: Indoco Remedies’ relationship with Aspen started with a simple contract manufacturing deal for 30 countries. However, in last two years the company was able to increase the scope and size of deal with Aspen. Currently Indoco Remedies has started validating batches. Revenue from Aspen is expected to start flowing in from Q4FY12 however full reflection of relationship would be visible in FY14. Watson: The agreement was initially signed for seven products however within last two years the number of products has increased to 19. The potential market size of these 19 products is $1.7bn. JV has filed for 8-9 products. Revenue is expected to start from FY14. In 1HFY12 Indoco remedies has signed two more contract-manufacturing deals in US. Such deals provide margin stability with revenue visibility for future. We believe CRAMS is a major growth driver for the company in coming period.”
“Currently exports contribute 10% of total revenues of the company. For semiregulated the company distributes its own products and for regulated markets (mainly Europe) it sells dossier bundled with five year supply agreement. Currently Indoco is earning 13-14% EBITDA margins in exports market. However, the company intends to increase the margins in future by changing product mix. Contribution from exports is also expected to go to 15% by FY13. Exports business is expected to grow by 25-30% in coming years, supporting the overall growth of the company. The company has grown at 22% CAGR over FY08-11. The company has debt/equity ratio of 0.29x (FY11). Although EBITDA Margins of the company have declined during financial meltdown (from 17.6% in FY07 to 14.0% in FY09) however, are now on growth trajectory (14.9% in FY11). Company has guided for 15.7% margins in FY12 and 19% by FY14. Management has also guided for Rs 1,000 cr revenues by FY14 (implying CAGR of 27% plus) with 19% EBITDA margins (post R&D). Currently API contribution is very small in the overall revenue pie of the company. The company intends to increase the APIs business and for that, it has planned capex of Rs 50 cr over next 18 months at Patalganga. We believe going forward APIs would provide second line of revenues in addition with backward integration benefits to the company in future.”
“Indoco Remedies took almost six decades to reach Rs 500 cr (FY12E) revenues mark however; it has set an aggressive target of adding another Rs 500 cr in next two years and expected to report Rs 1000 cr revenues in FY14. We believe the company is growing well and is now on the critical juncture where in it is expected to start enjoying the fruits of its past investments. We expect Indoco Remedies to post better 2HFY12 on the back of revival in domestic demand. For FY12 company has guided for 21% growth. On conservative basis (21% growth and 10.5% PAT margins, same as FY11) the stock is available at 8.2x FY12E earnings of Rs 50.3. . The stock can be purchased for long-term investment perspective,” says Nirmal Bang research report.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click here
Set email alert for
ADS BY GOOGLE
video of the day
Positive on PSU banks; NPA cycle may have peaked: Barclays